Clinical trials: Anticoagulant Drugs
Mild Head Injury, Anticoagulant
Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
Head trauma is a common injury in emergency department. Investigation to search for complication is guided by the clinical examination and the case history, such as taking anti-thrombotics.
- Conditions
- Mild Head Injury, Anticoagulant, Antiplatelet
- Trial name
- ISTCAT (NCT04305821)
- Testing
- Dosage of S100β protein
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Rennes University Hospital
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Wound Bleeding
Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154
The goal of this clinical trial is to test if the study drug, BXP154 works to stop bleeding from a minor wound in patients that are on anticoagulant therapy.
- Trial name
- NCT05837338
- Testing
- BXP154
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Bio 54, LLC
Hemostasis
Study of Hemostasis During the Atrial Fibrillation Ablation Procedure
Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial…
- Trial name
- EHPAFAVE (NCT05128110)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Atrial Fibrillation, Stroke
Patient Convenience Study (RE-SONANCE)
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02684981
- Where
- 12 sites in Austria, Bulgaria and 10 more
- Volunteers
- 9,472 people
- Sponsor
- Boehringer Ingelheim
AOD Prescription
Impact of Renal Function Availability to Community Pharmacist for Dispensing Direct Oral Anticoagulant in Ambulatory Patients on Bleeding Occurrence
The use of direct oral anticoagulants (AODs) in the prevention and treatment of thromboembolic diseases is increasing, with a favorable benefit/risk balance and improved quality of life for patients.
- Trial name
- Hemorrag-IR (NCT06739603)
- Testing
- pharmaceutical analysis
- Volunteers
- 1,920 people
- Sponsor
- Université de Reims Champagne-Ardenne
Drug Interaction
The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
This study aims to determine the nature and significance of the theoretical drug interaction between enzalutamide (a drug used to treat prostate cancer) and the direct-acting oral anticoagulant drugs (DOACs).
- Trial name
- ENZA-D (NCT03920566)
- Testing
- Anti-Xa level
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Atrial Fibrillation, Thromboembolism, Venous
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Aim of the study is to investigate whether the influence of drugs inducing of CYP 3A4 isoenzyme of CYP450 and P-gp transporter significantly affect plasma levels of DOACs in patients with NVAF and venous thromboembolism
- Trial name
- NCT05750680
- Testing
- DOACs
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Auricular Fibrillation, Anticoagulant Drugs
Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year
- Trial name
- NCT04133545
- Where
- Argentina
- Volunteers
- 360 people
- Sponsor
- Hospital Italiano de Buenos Aires
Anticoagulants and Bleeding Disorders
MAC Project, Monitoring of AntiCoagulant Therapies (MAC)
MAC Project is a prospective cohort, multicenter, observational, no-profit study aimed to prospectively collect reliable real-life clinical information in unselected VTE or NVAF patients treated with any DOAC, during a…
- Trial name
- MAC (NCT04329390)
- Testing
- Anticoagulant drugs
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Quovadis Associazione
Subject Under Anticoagulant
Prospective Real-world Registry Describing Treatment Regimens
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
- Trial name
- PRAETORIAN (NCT03942913)
- Testing
- an observational study
- Where
- France
- Volunteers
- 573 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Hematuria, Retention, Urinary
Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (TUR-BT) or transurethral resection of the prostate (TURP) or open prostatectomy (OP) due to…
- Conditions
- Hematuria, Retention, Urinary, Operative Bleeding, Blood Transfusion Complication
- Trial name
- NCT05314582
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Bezmialem Vakif University
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Atrial Fibrillation
Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
Atrial fibrillation is when the heart's two upper chambers (called atria) beat chaotically and irregularly, out of coordination with the two lower chambers (called ventricles) of the heart.
- Trial name
- NCT02964949
- Testing
- Edoxaban
- Where
- 233 sites in Belgium, Bulgaria and 13 more
- Volunteers
- 607 people
- Sponsor
- Daiichi Sankyo
Anticoagulant Prophylaxis/Therapy
Determination of Residual Anticoagulatory Effects of Fondaparinux
The purpose of this study is to determine residual anticoagulatory effects of a prophylactic or therapeutic fondaparinux treatment i.e. prior to surgery/intervention, after pause of therapy etc.
- Trial name
- NCT01101256
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Venous Thromboembolism
Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.
Venous thromboembolism (VTE) is a frequent multifactorial and potential life-threatening disease. Once VTE has been diagnosed, anticoagulation should be started and prolonged for at least three to six months in order to reduce…
- Trial name
- DEBRIEF-VTE (NCT04141254)
- Testing
- Debriefing and educative components, Without debriefing and educative components
- Where
- 10 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Venous Thrombosis or Pulmonary Embolism
What Treatment for Patients With Phlebitis or Pulmonary Embolism ?
The objective of the "anticoagchoice" study is to analyze the preferences of people suffering from phlebitis, in terms of anticoagulant, to improve adherence to these treatments, to adapt the medical prescriptions.
- Trial name
- AntiCoagChoice (NCT03889457)
- Testing
- anticoagulation choice
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Rennes University Hospital
Anticoagulant-related Major Bleed
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an…
- Trial name
- NCT05548777
- Testing
- Andexanet alfa, 4F-PCC
- Where
- United States
- Volunteers
- 5,480 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation
Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing prevalence AF. The purpose of paroxysmal AF processing is to control outbreaks from these pulmonary veins, medicated way (antiarrhythmic)…
- Trial name
- NACO-VP (NCT02814955)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Caen